Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA guidances

This article was originally published in The Gray Sheet

Executive Summary

Agency's Center for Devices and Radiological Health issues "Guidance Document for Vascular Prostheses 510(k) Submissions," developed "as a special control to support reclassification from Class III to Class II for vascular graft prostheses," Nov. 26. The center simultaneously issues "Guidance for Annuloplasty Rings 510(k) Submissions," also as a special control, and "Guidance for Cardiovascular Intravascular Filter 510(k) Submissions," which supersedes the agency's Feb. 11, 1997 guidance on premarket notification for the same devices. Draft "Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery" is also available for comment on CDRH web site

You may also be interested in...



Sandoz Pioneers Posaconazole And Silodosin In Canada

Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.

Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit

US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.

Dutch Supplements Firm Caught Buying Fake Instagram Followers

Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel